Does Haemonetics Stock Lead the Pack?
With Haemonetics surging 32% in a Day, it makes sense to re-evaluate vs its peers. Consistently assessing alternatives is core to a sound investment approach. Here is how Haemonetics (HAE) stock stacks up against its peers in size, valuation, growth and margin.
- HAE’s operating margin of 17.4% is strong, higher than most peers though lower than WST (20.9%).
- HAE’s revenue growth of -2.5% in the last 12 months is negative, lagging MMSI, CNMD, IART, WST but outpacing STAA.
- HAE’s stock is down 14.1% in last 1 year, and trades at a PE of 19.0; it underperformed STAA.
As a quick background, Haemonetics provides medical products and solutions, including automated plasma collection devices, blood component systems, disposables, and related software across plasma, blood center, and hospital segments.
A single stock can be risky, but there is a huge value to a broader, diversified approach. If you seek an upside with less volatility than holding an individual stock, consider the Trefis High Quality Portfolio (HQ). HQ has outperformed its benchmark — a combination of S&P 500, Russell, and S&P midcap index — and achieved returns exceeding 91% since its inception. Risk management is key — consider what the long-term portfolio performance could be if you blended 10% commodities, 10% gold, and 2% crypto with HQ’s performance metrics.
| HAE | MMSI | CNMD | STAA | IART | WST | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 3.2 | 5.1 | 1.4 | 1.3 | 0.9 | 19.9 |
| Revenue ($ Bil) | 1.3 | 1.5 | 1.3 | 0.2 | 1.6 | 3.0 |
| PE Ratio | 19.0 | 43.3 | 11.5 | -13.8 | -1.7 | 40.4 |
| LTM Revenue Growth | -2.5% | 11.4% | 4.3% | -32.6% | 5.0% | 4.9% |
| LTM Operating Margin | 17.4% | 11.4% | 13.8% | -36.4% | 1.9% | 20.9% |
| LTM FCF Margin | 19.3% | 13.8% | 12.5% | -19.5% | -0.9% | 12.6% |
| 12M Market Return | -14.1% | -15.6% | -40.7% | -13.7% | -58.0% | -16.1% |
Why does this matter? HAE just went up 34.2% in a week – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell HAE Stock to see if Haemonetics holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through HAE Dip Buyer Analysis lens.
Revenue Growth Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| HAE | -2.5% | 4.0% | 12.0% | 17.7% | |
| MMSI | 11.4% | – | 7.9% | 9.2% | 7.1% |
| CNMD | 4.3% | – | 5.0% | 19.1% | 3.4% |
| STAA | -32.6% | – | -2.6% | 13.4% | 23.4% |
| IART | 5.0% | – | 4.5% | -1.0% | 1.0% |
| WST | 4.9% | – | -1.9% | 2.2% | 2.0% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| HAE | 17.4% | 14.8% | 13.2% | 13.3% | |
| MMSI | 11.4% | – | 11.5% | 10.1% | 8.8% |
| CNMD | 13.8% | – | 15.3% | 9.7% | 6.7% |
| STAA | -36.4% | – | -4.0% | 8.7% | 15.4% |
| IART | 1.9% | – | 1.8% | 7.2% | 15.3% |
| WST | 20.9% | – | 20.4% | 24.0% | 26.4% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| HAE | 19.0 | 23.4 | 36.9 | 34.6 | |
| MMSI | 43.3 | – | 46.8 | 46.3 | 53.8 |
| CNMD | 11.5 | – | 15.9 | 52.1 | -33.0 |
| STAA | -13.8 | – | -59.0 | 70.9 | 58.7 |
| IART | -1.7 | – | -251.5 | 51.5 | 25.8 |
| WST | 40.4 | – | 48.5 | 44.1 | 29.9 |
While peer comparison is critical, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.